Guillain-Barre Syndrome Following Ad26.Cov2.S Covid-19 Vaccine: A Case Report

Authors

  • Sushmita Khanal Department of Intensive Care Unit, Department of Cardiology, Nobel Medical College Teaching Hospital, Biratnagar, Nepal https://orcid.org/0000-0001-8908-1887
  • Sunil Babu Khanal Department of Intensive Care Unit, Department of Cardiology, Nobel Medical College Teaching Hospital, Biratnagar, Nepal

DOI:

https://doi.org/10.3126/jonmc.v10i2.41790

Keywords:

COVID-19 Vaccines, Guillain-Barre Syndrome

Abstract

Guillain-Barre Syndrome has been reported as a rare side effect in the recipients of Johnson & Johnson®'s Janssen Ad26.COV2.S COVID-19 vaccine. We report a case of Guillain-Barre Syndrome in a 50 years old female following the administration of the aforementioned vaccine.

Downloads

Download data is not yet available.
Abstract
175
PDF
45

Author Biography

Sushmita Khanal, Department of Intensive Care Unit, Department of Cardiology, Nobel Medical College Teaching Hospital, Biratnagar, Nepal

Medical Officer

Downloads

Published

2021-12-31

How to Cite

Khanal, S., & Khanal, S. B. (2021). Guillain-Barre Syndrome Following Ad26.Cov2.S Covid-19 Vaccine: A Case Report. Journal of Nobel Medical College, 10(2), 63–64. https://doi.org/10.3126/jonmc.v10i2.41790

Issue

Section

Case Reports